NCT07067463View on ClinicalTrials.gov

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

705

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

June 30, 2030

Study Completion Date

July 31, 2030

Conditions

Multiple Sclerosis (MS) Primary Progressive

Interventions

DRUG

Orelabrutinib

Orally

DRUG

Placebo

Orally

All Listed Sponsors

lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY